ASCO 2022 | A Phase I dose escalation study of BiTEs targeting P-cadherin in solid tumors

James J. Harding, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of a Phase I dose escalation study (NCT02659631) of a bi-specific T-cell engaging therapy targeting P-cadherin in solid tumors. The study did not demonstrate significant anti-tumor activity and high levels of cytokine release syndrome was observed, providing key insight into the management and understanding of immune-related toxicities associated with bi-specific T-cell engaging therapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.